Risiko Kanker Hati pada Pasien dengan Penyakit Hati (Analisis Data Sampel BPJS Tahun 2019-2021)
DOI:
https://doi.org/10.30872/jkmm.v6i1.14311Keywords:
hepatitis, kanker hati, penyakit hati, survivalAbstract
Kanker hati adalah kondisi ketika sel-sel dalam hati tumbuh di luar kendali. Pada tahun 2020, kanker hati menempati urutan keempat kanker dengan jumlah kasus baru dan kematian tertinggi di Indonesia. Faktor risiko utama kanker hati adalah penyakit hati kronis. Tujuan penelitian ini adalah mengetahui risiko penyakit hati berkembang menjadi kanker hati pada peserta dengan dan tanpa penyakit hati di Indonesia tahun 2019-2021. Penelitian ini menggunakan Data Sampel BPJS Kesehatan tahun 2019-2021 dengan desain kohort retrospektif dan didapatkan jumlah sampel 824.592 terbobot. Analisis menggunakan uji Cox Proportional Hazard. Hasil penelitian menunjukan bahwa peserta dengan penyakit hati memiliki probabilitas dan risiko kanker hati yang lebih tinggi dibandingkan peserta yang tidak memiliki penyakit hati (CEP 1,61%; 95% CI 0,08% – 3,14%; AHR 98,5; 95% CI 40,6 – 239,4). Berdasarkan jenis dan jumlah penyakit hatinya, peserta dengan hepatitis kronis (AHR 153,9; 95% CI 32,3 – 690,7) dan menderita lebih dari 2 jenis penyakit hati (AHR 140,1; 95% CI 18,5 – 1061,7) memiliki risiko kanker hati paling tinggi dibandingkan kategori lainnya. Hasil studi menyimpulkan bahwa penderita penyakit hati, terutama hepatitis kronis, memiliki risiko sangat tinggi mengalami kanker hati. Untuk itu, perlu surveilans kanker hati secara nasional pada kelompok penduduk tersebut guna mencegah penyakit hati berkembang menjadi kanker hati.
References
Purnamasari D. The Emergence of Non-communicable Disease in Indonesia | Purnamasari | Acta Medica Indonesiana. Acta Med Indones - Indones J Intern Med [Internet]. 2018;50(4):273–4. Available from: http://www.actamedindones.org/index.php/ijim/article/view/1028/339
World Cancer Research Fund (WCRF) International. Worldwide cancer data | World Cancer Research Fund International [Internet]. World Cancer Research Fund (WCRF) International. 2022 [cited 2023 Feb 19]. Available from: https://www.wcrf.org/cancer-trends/worldwide-cancer-data/
World Health Organization. Cancer [Internet]. 2022 [cited 2023 Feb 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
The Global Cancer Observatory. Indonesia Fact Sheet [Internet]. International Agency for Research on Cancer. 2021 [cited 2023 Feb 19]. p. 1–2. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol [Internet]. 2022;77(6):1598–606. Available from: https://doi.org/10.1016/j.jhep.2022.08.021
McGlynn KA, Petrick JL, London WT. Global Epidemiology of Hepatocellular Carcinoma: An Emphasis on Demographic and Regional Variability. Clin Liver Dis [Internet]. 2015;19(2):223–38. Available from: http://dx.doi.org/10.1016/j.cld.2015.01.001
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
Maucort-Boulch D, Martel C de, Franceschi S, Plummer M. Intl Journal of Cancer - 2018 - Maucort‐Boulch - Fraction and incidence of liver cancer attributable to hepatitis B and C.pdf. 2018.
Suh JK, Lee J, Lee JH, Shin S, Tchoe HJ, Kwon JW. Risk factors for developing liver cancer in people with and without liver disease. PLoS One. 2018;13(10):1–13.
Kumar R, Priyadarshi RN, Anand U. Non-alcoholic fatty liver disease: Growing burden, adverse outcomes and associations. J Clin Transl Hepatol. 2020;8(1):76–86.
Zhang C hao, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2029–41.
World Health Organization. Regional Action Plan Of Hepatitis Viral In South East Asia 2016-2021. Vol. 2021, Genomic and Precision Medicine. 2017. 317–340 p.
Loho IM, Hasan I, Lesmana CRA, Dewiasty E. Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia : Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014. Asian Pacific J Cancer Prev Pacific J Cancer Prev [Internet]. 2016;17(4):2165–70. Available from: http://journal.waocp.org/?sid=Entrez:PubMed&id=pmid:27221913&key=2016.17.4.2165
Puri DA, Murti S, Riastiti Y. Insidensi dan Karakteristik Karsinoma Hepatoseluler di RSUD Abdul Wahab Sjahranie Samarinda. J Sains dan Kesehat. 2021;3(2):158–64.
Weledji EP, Enow G, Ngowe MN, Shey D. How grim is hepatocellular carcinoma ? Ann Med Surg [Internet]. 2014;3(3):71–6. Available from: http://dx.doi.org/10.1016/j.amsu.2014.06.006
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim [Internet]. 2021;7(1). Available from: http://dx.doi.org/10.1038/s41572-020-00240-3
Hu J, Liu K, Luo J. HIV–HBV and HIV–HCV Coinfection and Liver Cancer Development. In: DNA Tumor Viruses [Internet]. Springer International Publishing; 2019. p. 231–50. Available from: http://link.springer.com/10.1007/978-3-030-03502-0
Carlessi R, Köhn-Gaone J, Olynyk JK, Tirnitz-Parker JEE. Mouse Models of Hepatocellular Carcinoma. In: Hepatocellular Carcinoma [Internet]. Brisbane, Australia: Codon Publications; 2019. p. 69–94. Available from: https://exonpublications.com/index.php/exon/article/view/205
Constantin CV, Streba CT, Rogoveanu I, Nita-Stefanescu L, Ionescu AG. Cirrhosis and Chronic Viral Hepatitis as Risk Factors for Hepatocellular Carcinoma: Romanian Single-clinic Experience. Maedica (Buchar). 2010 Dec;5(4):265–70.
Zhao L-H, Liu X, Yan H-X, Li W-Y, Zeng X, Yang Y, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun [Internet]. 2016;7(1):12992. Available from: https://doi.org/10.1038/ncomms12992
Li H, Guo W, Xie Q, Sun X, Wang Q. Clinical characteristics and survival analysis of patients with hepatocellular carcinoma after hepatitis B virus turning negative. Adv Clin Exp Med. 2022;31(7):731–738.
Li L, Lan X. Association between hepatitis B virus/hepatitis C virus infection and primary hepatocellular carcinoma risk: A meta-analysis based on Chinese population. J Cancer Res Ther [Internet]. 2016;12(Special 3). Available from: https://journals.lww.com/cancerjournal/Fulltext/2016/12008/Association_between_hepatitis_B_virus_hepatitis_C.16.aspx
National Cancer Institute. Liver Cancer Causes, Risk Factors, and Prevention [Internet]. 2022 [cited 2023 Jun 18]. Available from: https://www.cancer.gov/types/liver/what-is-liver-cancer/causes-risk-factors
El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology. 2007;132(7):2557–76.
Downloads
Published
Issue
Section
License
The copyright of this article is transferred to Jurnal Kesehatan Masyarakat Mulawarman (JKMM) and when the article is accepted for publication. The authors transfer all and all rights into and to paper including but not limited to all copyrights in the Jurnal Kesehatan Masyarakat Mulawarman. The author represents and warrants that the original is the original and that he/she is the author of this paper unless the material is clearly identified as the original source, with notification of the permission of the copyright owner if necessary. The author states that he has the authority and authority to make and carry out this task.
The author states that:
- This paper has not been published in the same form elsewhere.
- This will not be submitted elsewhere for publication prior to acceptance/rejection by this journal.
A Copyright permission is obtained for material published elsewhere and who require permission for this reproduction. Furthermore, I / We hereby transfer the unlimited publication rights of the above paper to Jurnal Kesehatan Masyarakat Mulawarman. Copyright transfer includes exclusive rights to reproduce and distribute articles, including reprints, translations, photographic reproductions, microforms, electronic forms (offline, online), or other similar reproductions.
The author's mark is appropriate for and accepts responsibility for releasing this material on behalf of any and all coauthor. This Agreement shall be signed by at least one author who has obtained the consent of the co-author (s) if applicable. After the submission of this agreement is signed by the author concerned, the amendment of the author or in the order of the author listed shall not be accepted.
Rights / Terms and Conditions Saved
- The author keeps all proprietary rights in every process, procedure, or article creation described in Work.
- The author may reproduce or permit others to reproduce the work or derivative works for the author's personal use or for the use of the company, provided that the source and the Jurnal Kesehatan Masyarakat Mulawarman copyright notice are indicated, the copy is not used in any way implying the Jurnal Kesehatan Masyarakat Mulawarman (JKMM) approval of the product or service from any company, and the copy itself is not offered for sale.
- Although authors are permitted to reuse all or part of the Works in other works, this does not include granting third-party requests to reprint, republish, or other types of reuse.
Article Processing Charge
In order to improve the quality of articles, starting in June 2025 each article to be published in JKMM is subjected to a fee of IDR 550,000 or USD 34.
These fee include the costs of reviewing, translating, proofreading, layout, and publishing articles. Price does not include printed books and postage. The fee will be paid before entering the review process by reviewer.
More information about the Article Processing Charge, please Contact the journal representative through our number in footage information below.
